Layoffs
The pharma company will lay off 170 employees and drop all candidates but one, as it seeks to rebuild its business.
Takeda told BioSpace that the California layoffs are directly related to the recent cuts in Massachusetts.
Weeks after announcing a CEO shake-up and slightly decreased Q1 revenues, BMS plans to cut 48 staff members from its Princeton, NJ, facility.
Novartis is scaling back its pipeline to focus on higher-value assets with stronger commercial potential.
Following mixed Phase I/II data for its homocystinuria hopeful pegtarviliase, Aeglea lays off all but 10 employees and launches a sweeping strategic review.
The Boston Business Journal reported the layoffs would affect the multiple sclerosis team, but Biogen declined to confirm the details.
Almost two years after its launch, eye-focused gene therapy start-up Vedere Bio II is closing its doors, company leaders announced through a LinkedIn post over the weekend.
With some proactive measures, you can make it more likely your stocks will remain yours in the event of a layoff.
Amgen is terminating 450 workers in hopes of weathering dropping drug prices and rising inflation. This is Amgen’s second round of job cuts this year.
A recent report released by accounting and consulting firm BDO showed that over the course of 2023, 13% of life sciences companies may turn to layoffs in response to uncertain economic conditions.
PRESS RELEASES
